Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Poly(ADP-ribose) Polymerase Inhibitor”

52 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 52 results

Testing effectiveness (Phase 2)Ended earlyNCT04377087
What this trial is testing

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

Who this might be right for
Ovarian Cancer
Sarah E Taylor 3
Early research (Phase 1)Ended earlyNCT02500901
What this trial is testing

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

Who this might be right for
Metastatic Prostate Cancer
Paul Mathew, MD 2
Testing effectiveness (Phase 2)Study completedNCT01618136
What this trial is testing

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Who this might be right for
Malignant Solid TumourOvarian CancerTriple Negative Breast Cancer+2 more
Eisai Limited 41
Testing effectiveness (Phase 2)Study completedNCT05494580
What this trial is testing

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Who this might be right for
Ovarian CancerOvarian CarcinomaPlatinum-resistant Ovarian Cancer+2 more
Sun Yat-sen University 29
Testing effectiveness (Phase 2)Study completedNCT02878785
What this trial is testing

Decitabine and Talazoparib in Untreated AML and R/R AML

Who this might be right for
Acute Myeloid Leukemia
University of Maryland, Baltimore 25
Testing effectiveness (Phase 2)Ended earlyNCT01605162
What this trial is testing

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Who this might be right for
Wild Type BRAF Stage IV MelanomaUnresectable Stage III Melanoma
Eisai Inc. 8
Early research (Phase 1)Study completedNCT03343054
What this trial is testing

Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Who this might be right for
NeoplasmsBreast Neoplasms
Pfizer 28
Large-scale testing (Phase 3)Ended earlyNCT03642132
What this trial is testing

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

Who this might be right for
Ovarian Cancer
Pfizer 79
Early research (Phase 1)Ended earlyNCT01226901
What this trial is testing

A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)

Who this might be right for
NeoplasmsSolid Tumors
Merck Sharp & Dohme LLC 3
Early research (Phase 1)Looking for participantsNCT04511039
What this trial is testing

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Who this might be right for
Advanced Malignant Solid NeoplasmClinical Stage III Gastroesophageal Junction AdenocarcinomaClinical Stage IV Gastroesophageal Junction Adenocarcinoma+26 more
Roswell Park Cancer Institute 45
Testing effectiveness (Phase 2)Looking for participantsNCT07446855
What this trial is testing

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

Who this might be right for
Solid Tumours
AstraZeneca 180
Early research (Phase 1)Study completedNCT06650605
What this trial is testing

Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma

Who this might be right for
Glioma Glioblastoma Multiforme
Theragnostics Ltd 7
Early research (Phase 1)Study completedNCT03509636
What this trial is testing

Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer

Who this might be right for
Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd. 113
Testing effectiveness (Phase 2)Active Not RecruitingNCT01012817
What this trial is testing

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Who this might be right for
Metastatic Malignant Solid NeoplasmRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+2 more
National Cancer Institute (NCI) 88
Testing effectiveness (Phase 2)Study completedNCT03326193
What this trial is testing

Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 105
Testing effectiveness (Phase 2)WithdrawnNCT04239014
What this trial is testing

Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

Who this might be right for
Ovarian Cancer
AstraZeneca
Early research (Phase 1)Ended earlyNCT03944902
What this trial is testing

CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients

Who this might be right for
Ovarian CancerResistant BRCA Wild-Type Ovarian Cancer
University of Alabama at Birmingham 1
Testing effectiveness (Phase 2)Study completedNCT02116777
What this trial is testing

Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies

Who this might be right for
Adult Solid NeoplasmChildhood Solid NeoplasmRecurrent Childhood Central Nervous System Neoplasm+3 more
National Cancer Institute (NCI) 40
Early research (Phase 1)Ended earlyNCT01127178
What this trial is testing

Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors

Who this might be right for
Solid Tumors
Eisai Inc. 12
Early research (Phase 1)Looking for participantsNCT06121557
What this trial is testing

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 24
Next Page